Pancreatic Cancer Research

Clinical trialObservationalCompleted

Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Outcome
Finished, no results posted
Phase
Observational
Status
Completed
Study type
Observational
Start
10 August 2022
Ended
30 August 2025
Enrollment
19 participants
Sites
1
Primary outcomes
Pain severity-BPI; Pain severity-VAS; Pain severity-NRS; Quality of Life (EORTC PAN26); Quality of Life (EORTC C30)
Sponsor type
Academic / other
Results posted
No
Last update
28 April 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.